Volatile Week, but Green? Click to watch the new Podcast.

Calithera Biosciences Stock Forecast

NASDAQ:CALA BUY SELL

$2.56 (5.79%)

Volume: 86.597k

Closed: Jul 05, 2022

Hollow Logo Score: 0.992

Calithera Biosciences Stock Forecast

BUY SELL NASDAQ:CALA
$2.56 (5.79%)

Volume: 86.597k

Closed: Jul 05, 2022

Score Hollow Logo 0.992

Calithera Biosciences Company Profile

343 Oyster Point Boulevard

South San Francisco CA 94080

650-870-1000

www.calithera.com

Industry: Biotechnology

Sector: Healthcare

Calithera Biosciences

Description

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE